Welcome to Dilafor
Dilafor develops pharmaceutical products from heparin derivatives with low anticoagulant activity.
The company has a balanced product portfolio representing some highly promising ideas and innovations in obstetrics. Each of our projects addresses an important and unmet medical need.
All our drug development projects are based on Low Anticoagulant Heparin (LAH). Although standard heparin has numerous biological functions, its potential as a treatment for indications other than those currently approved is limited by its anticoagulative properties. Dilafor has produced several forms of LAH.
One of them, Tafoxiparin is presently in development for the prevention and normalization of protracted labor. An exploratory Proof of Concept phase II clinical study comprising a total of 263 women has been completed with promising results. Statistically significant shorter labor time was found in the group treated with tafoxiparin, in comparison to the one receiving placebo.
Most important, the results of the study gave Dilafor a solid base to plan in detail the further and ongoing clinical development program for a number of indications within the obstetric field.
